Freenome
FRNM
16.03
-0.33
-2.02%
Freenome
US · FRNM
#2882 by market cap
Listed 2024
16.03
-0.33
-2.02%
Live - 5344 symbols - heartbeat 484s ago
· 2026-10-08 06:49
Pre-market
15.62
-2.56%
After-hours
16.03
0.00%
- Market cap
- 1.72B
- P/E (TTM)i
- -6.71
- P/Bi
- -1.24
- EPSi
- -2.39
- Div yieldi
- 0.00%
- 52W posi
- 81%
Reader sentiment
Are you bullish or bearish on FRNM?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Weak
- Altman Z-Score is -4.09, below the 1.8 "distress zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 2 years
Latest year +955.14% YoY
Margins
- Gross margin
- 93.61%
- Operating margin
- -734.88%
- Net margin
- -721.31%
Key ratios & quality
- Enterprise valuei
- 1.62B
- Altman Z-Scorei
- -4.09
Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2024 | 2025 |
|---|---|---|
| Revenue | 2.88M | 30.41M |
| Gross profit | 318.00K | 28.47M |
| Selling & admin expenses | 63.78M | 52.12M |
| Research & development | 225.75M | 197.12M |
| Operating profit | -291.97M | -223.47M |
| Pretax profit | -274.42M | -219.34M |
| Tax | -- | -- |
| Net profit | -274.42M | -219.34M |
| Basic EPS | -3 | -2 |
| Diluted EPS | -2.65 | -2.07 |
| Line item |
|---|
| Revenue |
| Gross profit |
| Selling & admin expenses |
| Research & development |
| Operating profit |
| Pretax profit |
| Tax |
| Net profit |
| Basic EPS |
| Diluted EPS |
Balance sheet
| Line item | 2024 | 2025 |
|---|---|---|
| Total current assets | 252.60M | 226.49M |
| Cash & ST investments | 243.47M | 216.66M |
| Inventory | -- | -- |
| Total assets | 551.92M | 507.05M |
| Total current liabilities | 41.88M | 40.53M |
| Short-term debt | 5.04M | 10.11M |
| Long-term debt | -- | 102.50M |
| Total liabilities | 1,606,937,000.00 | 1,770,189,000.00 |
| Total equity | -1.06B | -1.26B |
| Retained earnings | -1.13B | -1.35B |
| Line item |
|---|
| Total current assets |
| Cash & ST investments |
| Inventory |
| Total assets |
| Total current liabilities |
| Short-term debt |
| Long-term debt |
| Total liabilities |
| Total equity |
| Retained earnings |
Cash flow
| Line item | 2024 | 2025 |
|---|---|---|
| Operating cash flow | -196.37M | -110.67M |
| Depreciation & amortization | 15.87M | 24.36M |
| Free cash flow | -256.78M | -131.72M |
| Dividends paid | -- | -- |
| Stock buybacks / issuance | -- | -- |
| Ending cash balance | 76.17M | 87.68M |
| Line item |
|---|
| Operating cash flow |
| Depreciation & amortization |
| Free cash flow |
| Dividends paid |
| Stock buybacks / issuance |
| Ending cash balance |
Returns & efficiency
| Line item | 2024 | 2025 |
|---|---|---|
| ROE %i | -- | -- |
| ROA %i | -50.96 | -41.43 |
| ROIC %i | -- | -- |
| 5-year avg ROE %i | -- | -- |
| EBIT margin %i | -9,521.89 | -712.04 |
| FCF / sales %i | -- | -- |
| Current ratioi | 6.03 | 5.59 |
| Quick ratioi | 5.85 | 5.38 |
| Debt / assetsi | 37.42 | 61.46 |
| LT debt / equityi | -- | -- |
| Interest coveragei | -- | -76.78 |
| Revenue CAGR (3Y) %i | -- | -- |
| Net income CAGR (3Y) %i | -- | -- |
| FCF CAGR (3Y) %i | -- | -- |
Revenue breakdown most recent period
Business
Development of an early cancer detection platform100.00%
Region
United States90.30%
International9.70%
Quote time 2026-10-08 06:49:02 · For reference only, not investment advice and not tailored to your situation.